Other News To Note
Thursday, March 31, 2011
Regulus Therapeutics Inc., of La Jolla, Calif., gained exclusive rights from New York University (NYU) to intellectual property covering methods of use in modulating microRNA-33a (miR-33a) and miR-33b for metabolic diseases such as atherosclerosis and metabolic syndrome. Scientists from Regulus and NYU have shown that antagonizing miR-33a and miR-33b with therapeutic oligonucleotide anti-miRs had several beneficial effects, including reduction in atherosclerotic plaque and increase in levels of high-density lipoprotein.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.